Simplify Logo
Iambic Therapeutics

Iambic Therapeutics

AI-driven discovery for oncology and neurology

Machine Learning Scientist - Clinical Prediction

Full-Time
$148k - $186k/yr
Mid, Senior
Master's, PhD
Remote in USA+1 more

More locations: Boston, MA, USA

Hybrid

Hybrid work is listed for Boston and remote-US arrangements.

About the job

Requirements
  • A Master of Science degree in chemistry, bio/chemical engineering, or a computational STEM field with at least 3 years of relevant industry or research experience, or a PhD or equivalent industry experience demonstrating comparable depth.
  • Strong Python experience, including implementing and fine-tuning deep learning models.
  • Demonstrated experience in clinical science or working with clinical datasets.
  • Strong data science skills covering problem framing, data sourcing, extraction, cleaning, visualization, exploratory data analysis, modeling, tuning, and communicating results.
  • Sufficient independence to own a workstream from data ingestion through evaluation.
  • Strong engineering habits, including reproducible experimentation, appropriate control strategy, clean code, and testing.
  • Comfort working with modern machine learning infrastructure such as Docker, CUDA, Kubernetes, and experiment tracking such as Weights & Biases.
Responsibilities
  • Fine-tune large-scale multimodal transformer models for clinical and biomedical applications.
  • Identify, characterize, and utilize datasets that can deliver insights into pharmacokinetics, pharmacodynamics, toxicity, clinical adverse events, and clinical trial outcomes.
  • Develop and apply rigorous experimental approaches that account for potential split, metadata, trial-family, temporal, ontological, and arm-comparator leakage.
  • Design and maintain benchmarking and evaluation frameworks that track model quality across models and tasks.
  • Build models with appropriate calibration, uncertainty quantification, and clinically meaningful evaluation metrics.
  • Collaborate with machine learning and software engineering colleagues to deploy and operationalize models.
  • Partner with clinical scientists and pharmacologists to ensure model development is grounded in drug discovery and development needs.
  • Communicate results to internal teams, external partners, and at conferences.
  • Generate high-quality research and engineering code by refactoring, testing, documenting, and packaging machine learning components.
Desired Qualifications
  • Experience building and deploying clinically relevant prediction models.
  • Familiarity with ClinicalTrials.gov/AACT data.
  • Experience with MedDRA, pharmacovigilance, or adverse event data.
  • Direct exposure to multi-task learning.
  • Hands-on experience with agentic data extraction.
  • HPC or large-scale computing experience.

About the company

Iambic Therapeutics develops therapeutics using an AI-driven discovery platform, focusing on oncology and neurological diseases in clinical-stage programs. The platform combines advanced AI models with automated experiments to predict molecular properties faster and with less data, speeding identification and optimization of drug candidates. It differentiates itself by maintaining an in-house pipeline alongside strategic pharmaceutical partnerships to advance programs and earn milestones and royalties. The goal is to bring new therapies to patients by accelerating discovery and development through AI and automation.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$303M

Headquarters

San Diego, California

Founded

2019

Get referred to Iambic Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda’s February 2026 deal provides upfront, research, and technology-access payments.
  • Bayer joined June 2026, expanding non-dilutive validation beyond oncology into broader drug discovery.
  • Iambic raised over $100 million in November 2025, supporting runway into 2028.

What critics are saying

  • Takeda’s billion-dollar value depends on milestones; failure in programs kills economics.
  • IAM1363 remains single-asset clinical proof; Phase 1b setbacks would crush credibility.
  • Big pharma can internalize AI discovery, and Bayer or Takeda can switch vendors.

What makes Iambic Therapeutics unique

  • NeuralPLexer and Enchant anchor Iambic’s AI stack for structure and endpoint prediction.
  • Takeda chose Iambic in February 2026, validating platform value with blue-chip pharma.
  • IAM1363 reached Phase 1/1b in two years, versus six-year industry averages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Company Match

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Intelligence360 News
Dec 3rd, 2025
Iambic Therapeutics raises $125M in new funding

Iambic Therapeutics has filed a notice with the US Securities and Exchange Commission for an exempt offering to raise $125 million in new funding. The filing was made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act, which allows companies to sell securities without registration under the Securities Act of 1933. Federal securities law requires such notices to be filed within 15 days after the first sale of securities in the offering. No additional details about the funding round, including investors or valuation, were disclosed in the filing.

Iambic Therapeutics
Nov 11th, 2025
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies

San Diego, CA – Nov. 10, 2025 – Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.

Endpoints News
Nov 10th, 2025
Iambic Therapeutics raises $100M funding

Iambic Therapeutics has secured over $100 million in a new funding round, as revealed by CEO Tom Miller. The investment comes from ARK and Regeneron, highlighting significant financial backing for the San Diego-based biotech company.

EntArabi
Jun 20th, 2024
Iambic Therapeutics raises $50M in Series B

Iambic Therapeutics, a US-based biotech company, raised $50 million in an expanded Series B funding round led by Mubadala Capital. The round included Qatar Investment Authority, Exor Ventures, and existing investors like Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners. This funding is part of a previous $100 million Series B round closed in October 2023. The funds will be used to advance Iambic's clinical and preclinical programs.

Pharmaceutical Business Review
Jun 19th, 2024
Iambic secures $50m to bolster clinical oncology programme pipeline

Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising clinical oncology programmes.